Intususseption

Rotavirus Vaccine Manufacturing Agreement Between BIOVIRx and IDT

Rotavirus Vaccine Manufacturing Agreement Between BIOVIRx and IDT. BIOVIRx and IDT announced today an agreement intended to develop the oral rotavirus vaccine RotaShield(R) for commercialization. Worldwide, rotavirus gastroenteritis causes more than 2 million hospitalizations and up to 600,000 deaths annually in infants and young children. BIOVIRx has an exclusive worldwide license for RotaShield(R) and is planning global commercialization upon appropriate regulatory approvals. IDT currently has existing vaccine production capacity for RotaShield(R) and has initiated construction of a new manufacturing facility for expanded production of the vaccine. The new facility will be located at the IDT complex in Dessau-Tornau, Germany.


Leonard P. Ruiz, CEO of BIOVIRx states, 'BIOVIRx is very pleased to be working with the well established vaccine manufacturer IDT, which has 80 years of vaccine manufacturing experience. This agreement will allow us to deliver to the world markets a safe, effective and affordable vaccine that can help in the prevention of a major disease problem and assist in saving the lives of 1,600 children lost every day due to this highly infectious virus'.

posted by Intussusception Medical Care Amateur - @ Intususseption: Rotavirus Vaccine Manufacturing Agreement Between BIOVIRx and IDT